收费全文 | 14323篇 |
免费 | 1942篇 |
国内免费 | 1051篇 |
耳鼻咽喉 | 121篇 |
儿科学 | 168篇 |
妇产科学 | 223篇 |
基础医学 | 1472篇 |
口腔科学 | 223篇 |
临床医学 | 2014篇 |
内科学 | 1920篇 |
皮肤病学 | 159篇 |
神经病学 | 639篇 |
特种医学 | 483篇 |
外国民族医学 | 5篇 |
外科学 | 1224篇 |
综合类 | 2857篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 1188篇 |
眼科学 | 302篇 |
药学 | 1679篇 |
38篇 | |
中国医学 | 1217篇 |
肿瘤学 | 1381篇 |
2024年 | 114篇 |
2023年 | 391篇 |
2022年 | 1016篇 |
2021年 | 1278篇 |
2020年 | 968篇 |
2019年 | 720篇 |
2018年 | 709篇 |
2017年 | 672篇 |
2016年 | 531篇 |
2015年 | 828篇 |
2014年 | 969篇 |
2013年 | 807篇 |
2012年 | 1061篇 |
2011年 | 1072篇 |
2010年 | 740篇 |
2009年 | 537篇 |
2008年 | 654篇 |
2007年 | 644篇 |
2006年 | 582篇 |
2005年 | 501篇 |
2004年 | 348篇 |
2003年 | 359篇 |
2002年 | 253篇 |
2001年 | 262篇 |
2000年 | 254篇 |
1999年 | 198篇 |
1998年 | 159篇 |
1997年 | 126篇 |
1996年 | 96篇 |
1995年 | 77篇 |
1994年 | 78篇 |
1993年 | 40篇 |
1992年 | 49篇 |
1991年 | 49篇 |
1990年 | 52篇 |
1989年 | 37篇 |
1988年 | 32篇 |
1987年 | 21篇 |
1986年 | 15篇 |
1985年 | 9篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1980年 | 2篇 |
1979年 | 1篇 |
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Methods and Results: This case-control association study contained 1673 samples, including 869 ophthalmic patients and 804 controls. Twelve tag SNPs have been selected from the MYP10 and MYP15 loci and genotyped by SNaPshot method. Among 12 SNPs, rs4840437 and rs6989782 in TNKS gene were found significant association with HM. Carriers of rs4840437G allele and rs4840437GG genotype created a low risk of high myopia (P = .036, OR = 0.81, 95%CI = 0.71–0.93; P = .016, OR = 0.73, 95%CI = 0.56–0.96; respectively). Carriers of rs6989782T allele and rs6989782TT+CT genotype also had a decreased risk of high myopia (P = .048, OR = 0.82, 95%CI = 0.71–0.94; P = .006, OR = 0.74, 95%CI = 0.59–0.92; respectively). Other 10 SNPs displaced nonsignificant association with HM. Additionally, the risk haplotype AC and the protective haplotype GT, generated by two SNPs in TNKS, were considerably more likely to be association with HM (for AC, P = .002 and OR = 1.26; for GT, P = .027 and OR = 0.84).
Conclusions: Our results demonstrated that some heritable variants in the TNKS gene are associated with HM in the Han population. The possible functions of TNKS in the development and pathogenesis of hereditary high myopia still require further researches to identify. 相似文献
Research design and methods: A sample of 1139 reports received by the Shaanxi ADR Monitoring Center from January 2015 to December 2017 was selected. ADR report quality was evaluated using an ADR report quality evaluation system.
Results: None of the reports were rated as excellent and 1.40% (n = 16) as good. Report quality was better for new and serious reports than for general reports. Medical institutions generated higher quality reports than pharmaceutical manufacturers. Nurses generated higher quality reports than doctors, pharmacists, and other professionals. Reporters of different occupations showed significant differences in the quality of the indicators Reporting time limit, Intervention ADR time, ADR termination time, ADR intervention measures, Original disease, and Cause of medication (P = 0.000).
Conclusions: The ADR data quality was poor in western China, and of lower quality than reported data from previous research in other regions. Improvements in the quality and availability of ADR reports are urgently needed. 相似文献